News of Note—FluGen, Roswell Park Cancer Institute and The Vaccine Group

FluGen rounds up more cash, FDA awards a new orphan drug designation and The Vaccine Group forms.

> Madison, Wisconsin-based FluGen reeled in $5.5 million as it prepares for three tests on a universal flu vaccine candidate next year. Xconomy story

> The FDA awarded an orphan drug designation for a glioblastoma vaccine candidate developed at the Roswell Park Cancer Institute. Release

> A spinoff from the University of Plymouth dubbed The Vaccine Group formed to work on vaccines against pathogens such as avian influenza A, Ebola and Marburg viruses, MERS and SARS. Release

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.
Read more on

Suggested Articles

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

As Merck and Pfizer race to market with next-gen vaccines, the companies are fighting in court over a trade secrets lawsuit from Merck.

After working with the government for years to advance a next-gen smallpox vaccine, Bavarian Nordic has finally scored its approval.